Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Evommune Inc (EVMN)

Evommune Inc (EVMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MarketBeat.com
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 MarketBeat - Mon Jan 19, 10:28AM CST

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 18.40 (+9.52%)
ATAI : 3.85 (+5.77%)
CRMD : 6.88 (+1.47%)
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire - Thu Dec 11, 2025

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized...

EVMN : 18.40 (+9.52%)
Evommune Announces Pricing of its Initial Public Offering PR Newswire - Wed Nov 5, 2025

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 18.40 (+9.52%)
Evommune Announces Commencement of Initial Public Offering PR Newswire - Thu Oct 30, 2025

PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory...

EVMN : 18.40 (+9.52%)

Barchart Exclusives

Trump’s Greenland Threats Scaring You Off? Buy This Dividend Stock as a Hedge Barchart - Tue Jan 20, 6:30PM CST
Trump's threats to seize Greenland have led to a selloff in risk assets while precious metals have rallied amid the flight to safe-haven assets. Agnico-Eagle Mines is a good dividend stock to buy amid the geopolitical turmoil. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot